Previous 10 | Next 10 |
Endo International (ENDP) has agreed to acquire all of the outstanding shares of BioSpecifics Technologies (BSTC) for $88.50 per share in cash, representing an aggregate equity value of ~$540M (net of ~$120M in cash acquired).Under the terms of the merger agreement, Endo through a ...
Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™ Canada NewsWire DUBLIN, Oct. 19, 2020 -- Endo to acquire BioSpecifics in an accretive all-cash transaction -- DUBLIN , Oct. 19, 2020 /CNW/ -- Endo International pl...
The following slide deck was published by BioSpecifics Technologies Corp. in conjunction with this Read more ...
WILMINGTON, Del. , Sept. 14, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North Ame...
WILMINGTON, Del. , Sept. 8, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in Nort...
BioSpecifics Tech (NASDAQ: BSTC ) : Q2 Non-GAAP EPS of $0.11 beats by $0.16 ; GAAP EPS of $0.02. Revenue of $3.9M (-55.9% Y/Y) beats by $1.84M . Press Release More news on: BioSpecifics Technologies Corp., Earnings news and commentary, Healthcare stocks news,
WILMINGTON, Del. , Aug. 10, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North Amer...
Investment Thesis BioSpecifics Technologies Corp. 5-year share price performance. Source: TradingView BioSpecifics ( BSTC ) is a small microcap with a market cap of just $474m and revenues of $38.1m in 2019, but the company is entering an exciting phase in its development with the recent...
Original post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
WILMINGTON, Del. , July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in ...
News, Short Squeeze, Breakout and More Instantly...
BioSpecifics Technologies Corp Company Name:
BSTC Stock Symbol:
NASDAQ Market:
BioSpecifics Technologies Corp Website:
Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer PR Newswire DUBLIN, Nov. 18, 2020 DUBLIN , Nov. 18, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) (" Endo ") today announced the expiration of th...
New York, New York--(Newsfile Corp. - November 13, 2020) - Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether BioSpecifics Technologies Corp. (NASDAQ: BSTC) agreement to be acqui...
BioSpecifics Reports Third Quarter 2020 Financial and Operating Results - Endo acquisition of BioSpecifics expected to close in 4Q20 PR Newswire WILMINGTON, Del., Nov. 9, 2020 WILMINGTON, Del. , Nov. 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp....